Urodelia & 4P-Pharma announce a business development partnership in Animal Health for Apa.vac® anticancer therapeutic vaccine

Urodelia, a Toulouse (France) biotech company specialized in personalised anti-cancer therapeutic vaccine, and 4P-Pharma, a Lille (France) biotech company specialised in human and animal drug development, are pleased to announce that they established a business development partnership. As an exclusive partner, 4P-Pharma will seek strategic opportunities in Animal Health for the licensing-out of Urodelia’s Apa.vac® anticancer therapeutic vaccine.

Read the full press release
English version: PR_Urodelia_4P-Pharma_EN
French version: PR_Urodelia_4P-Pharma_FR


Press Contacts:
Urodelia press contact

Camille Bayol, Project Manager
Phone: +33 (0)5 34 47 86 10 – E-mail: Camille.bayol@urodelia.com

4P-Pharma press contact
Roselina Lam, Business developer
Phone: +33 (0)9 50 72 97 68 – E-mail: roselina@4p-pharma.com

Happy Holidays!

4P-Pharma team wishes you a happy holidays season. We believe that with hard work, imagination and a strong team spirit everything is achievable, and the dream that you were pursuing  becomes right there for you to grab!


drawing by: Johan Toggenburger


Our collaboration with Elsevier’s The Hive program continues with a new blog post entry!  In our previous blog post we detailed how Elsevier’s suite of R&D solutions have been helping us in boosting our Research (Read it here). This time we focus on our business model of partnerships and co-development to detect and develop promising technologies in the field of cancer and inflammatory diseases.

Read our latest blog post: https://pharma.elsevier.com/pharma-rd/leveraging-partnerships-rescue-develop-promising-technologies/


The Hive_4PPharma